There’s a good chance that the vast majority of people who receive it won’t derive any benefits whatsoever. But that isn’t stopping British drug giant GlaxoSmithKline (GSK) from seeking regulatory approval for a new vaccine for malaria, known as RTS,S, that a recent study determined is only about30 percent effective at preventing severe cases of the disease, which has no recognized cure …. http://www.naturalnews.com